Science Board meeting
FDA's Science Board will wrap up its review of FDA's drug safety programs March 31; during a meeting in November, the agency outlined a restructuring of its drug safety operations (1"The Pink Sheet" Nov. 7, 2005, p. 3). The panel will also discuss a request from FDA to review the agency's science program. The meeting will be held at 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m...
You may also be interested in...
The Center for Drug Evaluation & Research will divide its drug safety functions between a new associate center director and its existing Office of Drug Safety
Vacancies Reform Act requires individual in an acting position to step down in order to be nominated to the permanent post but there are exceptions. Andrew von Eschenbach retained acting title during his nomination in 2006.
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.